RxDoctor Payments Data

Jonathan Salcedo, MD

Clinical Cardiac Electrophysiology · Redwood City, CANPI 1699905190

Payments from drug & device makers

$78,360in general payments, 2019–2025

Across 268 payments — averaging $292.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$45K
  • Medtronic$12K
  • Medical Device Business Services, Inc.$8K
  • Boston Scientific$4K
  • Biosense Webster, Inc.$3K
  • Impulse Dynamics (USA) Inc.$1K
  • plus $5K from 19 others

What the payments were for

  • Consulting fees$21,12651%
  • Speaking & faculty fees$3,6009%
  • Travel & lodging$1,8614%
  • Food & beverage$14,82136%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,360 in reported general payments places this provider in the 65th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$495,233
Medicare patients
804
Services billed
3,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban272$374,001
XareltoRivaroxaban57$62,905
EntrestoSacubitril/Valsartan19$31,572
JardianceEmpagliflozin12$17,995
Dofetilide34$9,516
Flecainide Acetate47$4,117
Metoprolol Succinate108$1,861
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,797
Atorvastatin Calcium84$1,285
SotalolSotalol Hcl49$1,143
Sotalol AfSotalol Hcl57$1,131
Telmisartan11$608
Olmesartan Medoxomil35$600
Digoxin18$552
Valsartan13$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$374,001272 claims
Johnson & JohnsonXarelto$35$62,90557 claims
NovartisEntresto$89$31,57219 claims
Boehringer IngelheimJardiance$21$17,99512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Redwood City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →